secwatch.observer — SEC 8-K summary
======================================

Issuer:     Karyopharm Therapeutics Inc. (KPTI)
CIK:        0001503802
Form:       8-K
Filed at:   2023-08-02T23:59:59+00:00
Accession:  0001193125-23-201161
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Karyopharm Q2 total rev $37.6M; net loss $32.6M; cuts workforce 20%, guides FY rev $145-160M
--------------------------------------------------------------------------------

- Q2 total rev $37.6M (down 5% YoY); net loss $32.6M ($0.29/sh) improved from $49.1M ($0.62/sh).
- U.S. XPOVIO net product rev $28.5M (flat YoY); FY 2023 guidance: total rev $145-160M, XPOVIO $110-125M.
- Workforce cut ~20%; non-GAAP R&D+SG&A guidance lowered to $240-255M; cash runway extended into late 2025.
- Initiated pivotal Phase 3 (XPORT-MF-034) of selinexor+ruxolitinib in JAKi-naïve myelofibrosis; Fast Track from FDA.
- Revenue Interest Financing amended: cap raised to 195%, warrants for 250k shares at $2.25, payment date extended to June 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1503802/000119312523201161/0001193125-23-201161-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1503802/000119312523201161/d542880d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-201161

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer